Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01442103 · ClinicalTrials.gov registry record · NA

Clinical Utility of a New Silver Gel for Use on Chronic Wounds

A NA study of Chronic Wounds, sponsored by Molnlycke Health Care AB.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT01442103 is a NA study of Chronic Wounds that has completed, run by Molnlycke Health Care AB. The registered enrollment target is 10 participants, below the 183-participant average among 4 other Chronic Wounds trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01442103, a NA study of Chronic Wounds, has completed, sponsored by Molnlycke Health Care AB.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This investigation will be conducted in the US as a single-center study to evaluate in total 10 subjects, to explore the clinical utility of a new silver gel for use on chronic wounds.

Conditions Studied

Interventions

  • DEVICE Normlgel Ag

Study Locations (1)

Georgia

  • Joseph M. Still Research Foundation, Inc. - Augusta

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2011-09
Est. Completion 2012-05
Phase NA

Sponsor

Molnlycke Health Care AB

20 total trials

What the Registry Record Tells You About NCT01442103

The ClinicalTrials.gov registry entry for NCT01442103 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 4 other Chronic Wounds trials with a reported enrollment target (95% lower). The listed sponsor is Molnlycke Health Care AB, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Wounds appearing as the primary indexed condition, and to 1 intervention - of which Normlgel Ag is the first listed.

NCT01442103 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT01442103 about?

NCT01442103 is a clinical study titled "Clinical Utility of a New Silver Gel for Use on Chronic Wounds". This investigation will be conducted in the US as a single-center study to evaluate in total 10 subjects, to explore the clinical utility of a new silver gel for use on chronic wounds.

What is the current status of trial NCT01442103?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2011-09. Estimated completion is 2012-05.

What conditions does trial NCT01442103 study?

This clinical trial studies the following conditions: Chronic Wounds.

What interventions are being tested in trial NCT01442103?

The interventions under investigation include: Normlgel Ag (DEVICE).

Who is sponsoring clinical trial NCT01442103?

This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01442103 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Wounds

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.